Starting
treatment
Indications
Dosing
and monitoring
Complications
Follow-up
|  |  | | Dosing
and monitoring |
Start warfarin as soon as possible a and monitor its effect using INR.
a
For patients with venous thromboembolism, give LMWH or heparin while awaiting satisfactory oral anticoagulation.
a
Give heparin
d and LMWH
d
for a minimum of 5 days and continue for 2 days after the INR is within therapeutic range
d Use a set dosing regimen (preferably by computer)
a and seek expert advice when indicated.
a
Here is an example dosing regimen to achieve a therapeutic range of INR 2.0 to 3.0.
b
Give the warfarin at 5 to 6 pm, and measure the INR at 9 am the next day.
Monitor INR daily until in range and stable.
Use lower loading doses - they are more effective
a
Warfarin dosing regimen to achieve INR 2.0 to 3.0
b
|
Dose for age (mg)
|
| Day |
INR |
up to 50 |
51 to 65 |
66 to 80 |
> 80 |
| 1 |
<1.4 |
10 |
9 |
7.5 |
6 |
| |
|
|
|
|
|
| 2 |
<1.6 |
10 |
9 |
7.5 |
6 |
| |
> 1.6 |
0.5 |
0.5 |
0.5 |
0.5 |
| |
|
|
|
|
|
| 3 |
<1.8 |
10 |
9 |
7.5 |
6 |
| |
1.8 to 2.5 |
4.0 to 5.0 |
3.5 to 4.5 |
3.0 to 4.0 |
2.5 to 3.0 |
| |
2.6 to 3.0 |
2.5 to 3.5 |
2.5 to 3.5 |
2.0 to 2.5 |
1.5 to 2.0 |
| |
3.1 to 3.5 |
1.0 to 2.0 |
1.0 to 2.0 |
0.5 to 1.5 |
0.5 to 1.5 |
| |
3.6 to 4.0 |
0.5 |
0.5 |
0.5 |
0 |
| |
> 4.0 |
0 |
0 |
0 |
0 |
| |
|
|
|
|
|
| 4 |
< 1.6 |
10.0 to 15.0 |
9.0 to 13.0 |
7.5 to 11.0 |
6.0 to 9.0 |
| |
1.6 to 1.9 |
6.0 to 8.0 |
5.5 to 7.0 |
4.5 to 6.0 |
3.5 to 5.0 |
| |
2.0 to 2.6 |
4.5 to 5.5 |
4.0 to 5.0 |
3.5 to 4.5 |
2.5 to 3.5 |
| |
2.7 to 3.5 |
3.5 to 4.0 |
3.0 to 3.5 |
2.5 to 3.0 |
2.0 to 2.5 |
| |
3.6 to 4.0 |
3 |
2.5 |
2 |
1.5 |
| |
4.1 to 4.5 |
omit next day's dose,
then 1.0 to 2.0 |
omit next day's dose,
then 1.0 to 2.0 |
omit next day's dose,
then 1.0 to 2.0 |
omit next day's dose,
then 1.0 to 2.0 |
| |
> 4.5 |
nil: hold dose |
nil: hold dose |
nil: hold dose |
nil: hold dose |
Decrease the
dose by 33% if the patient has one or more of the following risk
factors:
-
Severe
congestive heart failure (ejection fraction < 30% and/or
biventricular failure)
-
Severe
chronic obstructive airways disease (oxygen or steroid use or
dyspnoea at rest)
-
Concurrent
amiodarone use.
|